EUCTR2015-005497-38-GB进行中（未招募）1 期
Effects of TAMoxifen on the Mutant Allele Burden and Disease Course in Patients with MyeloprolifeRatIve Neoplasms - TAMARI
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age = 60 years (men aged between 50-59 may also be considered following discussion with the Chief Investigator)
- •Women must be post-menopausal (defined as amenorrhoeic for at least 12 consecutive months following cessation of all exogenous hormonal treatments)
- •Confirmed diagnosis of JAK2-V617F or CALR 5bp insertion (exon 9) or CALR 52bp deletion (exon 9) positive Essential Thrombocythaemia (ET), Polycythaemia Vera (PV) or Myelofibrosis (MF) (primary or secondary) for = 6 months
- •JAK2-V617F or CALR 5bp insertion (exon 9) or CALR 52bp deletion (exon 9)mutant allele burden = 20% in peripheral blood granulocyte DNA at study entry (assessed via central review)
- •WHO performance status 0-2
- •For patients with PV or ET, maintenance of platelet count =600 x 10^9/L, WBC =25 x 10^9/L and venesection requirements =1 per month for the previous 3 months (prior to registration), without introduction of any new therapeutic agents for their MPN for 6 months prior to registration
- •For patients with MF, there must not have been any evidence of disease progression* for the previous 6 months (prior to registration) and no new therapeutic agents for their MPN introduced during this period.
- •Patients receiving cytoreductive therapy (with the exception of interferon alpha or investigational agents) for their MPN (not solely aspirin or venesection)
- •Adequate hepatic function, defined as:
- •o bilirubin = 1.5 x upper limit of normal (ULN) (patients with elevated bilirubin due to Gilbert’s syndrome are eligible)
- •o AST/ALT/ALP = 2.5 x ULN
- •Adequate renal function (creatinine clearance >30 mL/min)
- •Male patients must agree to use effective contraception during participation in the trial and for 2 months after the last dose of trial treatment
- •Patient must be able to give written informed consent
- •*Defined by IWG-MRT ELN criteria (Appendix 6). Please note no baseline bone marrow is required to confirm absence of Leukemic transformation confirmed by a bone marrow blast count of =20%”.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 32
排除标准
- •Leukaemic transformation (>20% blasts in blood, marrow or extramedullary site).
- •Accelerated phase of disease as indicated by >10% blasts in the peripheral blood
- •Treatment of ET, PV or MF with Interferon alpha or other investigational agents for their MPN within 6 months prior to trial entry. JAK inhibitors, such as ruxolitinib, are allowed if taken continuously for =6 months prior to registration (dose changes during that period will be allowed)
- •Any of the following previous thrombotic events at any time:
- •o Portal or other splanchnic venous thrombosis
- •o Vascular access complication
- •o Ischemia cerebrovascular
- •o Transient Ischaemic attack
- •o Superficial thrombophlebitis
- •o Venous Thromboembolic events including pulmonary embolism (PE) and deep vein thrombosis (DVT)
- •o Peripheral vascular ischemia
- •o Visceral arterial ischemia
- •o Acute coronary syndrome
- •o Myocardial infarction
- •Previous malignancy within 5 years with the exception of adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer
- •Previous endometrial cancer, hyperplasia or polyps
- •Prior treatment with hematopoietic stem cell transplantation
- •Patients who do not carry JAK2V617F, CALR 5bp insertion (exon 9) or CALR 52bp deletion (exon 9) mutations, or whose allele burden is <20% at study entry
- •Female patients receiving hormone replacement therapy
- •Hypertriglyceridemia > grade 1
- •Any serious underlying medical condition (at the judgment of the Investigator), which could impair the ability of the patient to participate in the trial (e.g. liver disease, active autoimmune disease, uncontrolled diabetes, uncontrolled infection (HIV, Hepatitis B and C), known genetic defect (apart from MPN) relating to venous thromboembolic events, or psychiatric disorder precluding understanding of trial information)
- •Known hypersensitivity to tamoxifen or hypersensitivity to any other component of tamoxifen
- •Concomitant drugs contraindicated for use with the trial drug according to the Summary of Product Characteristics
- •Known planned scheduled elective surgery during study with the exception of dental and low risk eye surgery (e.g. cataracts)
研究者
相似试验
已完成
不适用
Effects of tamoxifen in patients with myeloproliferatIve disordersMyeloproliferatIve neoplasmsChronic myeloproliferative diseaseCancerISRCTN65011803niversity of Birmingham38
已完成
2 期
Evaluation of the effects of increasing tamoxifen dose on the treatment process in breast cancer patientsBreast cancer.Malignant neoplasm of breastIRCT2015082323734N1Isfahan University of Medical Siences100
招募中
1 期
Breast cancer prevention in women at increased risk using low dose tamoxifen and/or diet and life style changes: a randomized 4 arms clinical studyHealthy women aged 18-70 either carriers of a germline pathogenetic variant (BRCA1, BRCA2, PALB2, ATM, CHEK2, CDH1, RAD51C or RAD51D) or with a breast cancer risk >5% at 10 years (according to the Tyrer-Cuzick model or the Breast Cancer Surveillance Consortium Risk models) or with a previously treated breast IEN (intraepithelialneoplasia).MedDRA version: 21.1Level: PTClassification code: 10006189Term: Breast cancer in situ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10022779Term: Intraductal breast cancer (in situ) Class: 10029104CTIS2023-503994-39-00European Institute Of Oncology S.r.l.200
招募中
1 期
Pharmacokinetics and pharmacogenomics of Tamoxifen in healthy volunteers: The effects of African specific CYP2D6*17 genotype on the plasma levels of Tamoxifen and its metabolitesCancerPACTR202106791732070AiBST42
已完成
不适用
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast CancerBreast NeoplasmsTamoxifenNCT00830973Medco Health Solutions, Inc.184